TWiki . Edumacation . StockPumpingSpecialSituationsAlert20020807 TWiki . { Main | Edumacation | TWiki | Test }
Edumacation . { Home | Users | Changes | Search | Go }
linked from Stock Pumping Equity Alert web search for Stock Pumping Equity Alert
Received: from ([]) by with Microsoft SMTPSVC(5.0.2195.4905);
    Wed, 7 Aug 2002 18:57:47 -0700
Received: (qmail 1553 invoked from network); 8 Aug 2002 01:18:09 -0000
Received: from unknown (HELO SSA) (
  by with SMTP; 8 Aug 2002 01:18:09 -0000
From: "Equity Alert Center" <>
Reply-To: "Equity Alert Center" <>
X-EAMsgID: 07-Aug-2002:_:ssaRMDC:_:729250
MIME-Version: 1.0
Content-Type: multipart/alternative; boundary=NextPart_ESPAlert_1_0___000_spk
Message-ID: <>
X-OriginalArrivalTime: 08 Aug 2002 01:57:47.0985 (UTC) FILETIME=[FEB4AC10:01C23E7E]
Date: 7 Aug 2002 18:57:47 -0700

Special Situations Alert

  • Our last Special Situations Alert gained 29% immediately after our introduction. This week, we present RUBICON MEDICAL, INC. (OTC BB: RMDC) named as one of the TOP 100 public companies by Utah business (May 2002).
  • RMDC has developed some of the most advanced patented medical devices that treat and prevent complications in interventional cardiology, radiology and peripheral interventional radiology a $1 Billion market!

  • RMDC has already licensed its technology to Abbott Labs (NYSE: ABT) in a deal worth almost 30 cents a share to the company !! Amazingly, RMDC trades at just 40 cents per share !

  • With other significant products in the pipeline, 756% annual increase in revenues since 1999, experienced management and a relatively low priced stock, watch for strong investor interest in RMDC in the near future.


    Rubicon Medical Announces Plans for a CE Mark Clinical Study
    To Obtain Regulatory Approval in Europe for the Rubicon Filter

    SALT LAKE CITY, Aug. 5 /PRNewswire-FirstCall/ -- Rubicon Medical Corporation (OTC Bulletin Board: RMDC), a developer and manufacturer of medical devices and products, today announced plans for a CE Mark clinical study of the Rubicon Filter in Europe. The study will test the Rubicon Filter in saphenous vein grafts (SVGs), which are degenerated coronary bypass grafts in which blockages have reappeared following heart bypass surgery. The CE Mark is the regulatory approval that must be obtained in order to market a medical device in the European Union.

    "We will soon begin the process for regulatory approval of the Rubicon Filter in the European Union for SVG patients. Our research and development team has worked under an accelerated schedule, and we plan to commence clinical studies in either the 4th quarter of 2002, or 1st quarter of 2003. These studies are anticipated to take 3-4 months to complete," stated Mr. Richard J. Linder, Rubicon President and CEO. Linder also noted that "We have completed feasibility testing at the Utah Artificial Heart Institute, and we plan to begin the FDA approval process after the CE Mark studies have been completed."

    The Rubicon Filter is an embolic filter, a medical device designed to be inserted into a blood vessel and allow blood to continue flowing during a surgical procedure, while blocking any particle large enough to cause damage to the body. During many coronary vascular procedures, a principal risk is that plaque material from a coronary blockage can be dislodged to travel through the body. Such loose particles can block other blood vessels (a condition called embolization) and cause a stroke, heart attack or other very serious problem. The Rubicon Filter is designed to prevent or reduce the possibility of serious or fatal embolization caused by such loose particles. In addition, the Rubicon Filter is the smallest known embolic protection filter device in existence. Although similar devices currently are in use in other countries, no other filter device similar to the Rubicon Filter has yet been approved for use in the United States. When inserted into a coronary artery past an atherosclerotic (plaque) blockage, the Rubicon Filter's extremely small size will greatly reduce the risk of breaking free particles that can cause serious injury to the patient during passage of the filter.

    The Rubicon Filter's small size also means it will be much simpler and easier for surgeons to navigate it through coronary arteries. Rubicon believes that the filter's advanced features and ease of use will present a significant improvement for interventional physicians over existing filter technologies marketed by Boston Scientific, Guidant, Medtronic and Cordis (Johnson & Johnson). The worldwide market for embolic protection devices such as the Rubicon Filter is estimated at a potential $1 billion dollars annually.

    "The commencement of European studies re-affirms our commitment to conduct our own clinical studies, grow our business and to market our own proprietary technologies worldwide. We believe that once we obtain regulatory approvals, the Rubicon Filter will become a standard choice of interventional physicians," Mr. Linder continued.

    Randall Higashida, MD, Rubicon's Medical Director, stated: "I am very excited with the efforts Rubicon has invested in the Rubicon Filter for SVG patients. The Rubicon Filter, once approved in the U.S. and Europe, holds the potential to make these coronary procedures safer for SVG patients, and we intend to establish this through clinical research." Dr. Higashida is the Chief of Interventional Neuro-Radiology at the University of California at San Francisco, President of the American Society of Interventional Therapeutic Neuroradiology (ASITN), and Chairman of the American Heart Association's Committee on Cerebrovascular Disease.

    About Rubicon Medical

    Rubicon Medical Corporation is a Salt Lake City-based developer and manufacturer of interventional vascular medical devices and products. The Company focuses on minimally invasive endovascular techniques and products that are safer and more cost effective than surgery. Rubicon was proud to be named one of the Top 100 Utah public companies by Utah Business magazine in May 2002.

    Rubicon has licensed a different embolic protection product, the Guardian system, to Abbott Laboratories, which will conduct the FDA regulatory approval process for the Guardian in the United States and also the CE Mark clinical study program in Europe.


    All forward-looking statements in this release are based upon information available to the Company on the date of this release. Any forward-looking statements involve risks and uncertainties, including those risks and uncertainties described in the Company's filings with the Securities and Exchange Commission, that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, whether as a result of new information, future events or otherwise. The Rubicon Filter and Guardian devices have not yet been approved for sale in the U.S. or Europe, and no assurance exists that such approvals will be obtained; Readers should not place undue reliance on these forward-looking statements.



    The purpose of this advertisement, like any advertising, is to provide coverage and publicity for the advertising company, its products or services. The information provided in this advertisement is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country. Verify all claims and do your own due diligence. This advertisement is not a solicitation or recommendation to buy, sell or hold securities and does not provide an analysis of the financial position of the company. We recommend you use the information found in this advertisement as an initial starting point for conducting your own research on the advertised company in order to determine your own personal opinion of the company before investing. All information concerning the advertised company contained herein should be verified independently by an attorney, with such company and an independent licensed securities analyst. We are not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. Many states have established rules requiring the approval of a security by a state security administrator. Check with and call your state security administrator to determine whether a particular security is licensed for sale in your state. Many companies have information filed with state securities regulators and many will supply investors with additional information on request. All statements and opinions contained in this advertisement are the sole opinion of the authors and are subject to change without notice. We are not liable for any investment decisions by our readers. Readers should independently investigate and fully understand all risks before investing. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser or broker prior to completing any such purchase or sale decision. We are not registered investment advisers, or broker-dealers, or members of any financial regulatory bodies. The information contained in this advertisement is provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. We disclaim any and all liability as to the completeness or accuracy of the information and for any omissions of material facts. This advertisement may contain hyperlinks to web sites operated by third parties other than us. Such hyperlinks are provided for the reader's reference and convenience only. We are not responsible for the reliability of these external sites nor are we responsible for any of the contents, advertising, products, or other materials on such external sites. EQOur inclusion of hyperlinks to such web sites does not imply any endorsement of the material on such web sites or any association with their operators. Under no circumstances shall we be held responsible or liable, directly or indirectly, for any loss or damage caused or alleged to have been caused in connection with the use of or reliance on any content, goods, or services available on such external site. Any concerns regarding any external link should be directed to its respective site administrator or webmaster. We may refer to other sources of information, or other commentary. We intend to offer these items to readers as additional sources of information, but disclaim any implication that we endorse information contained in such outside sources. Any referral by us is no guarantee of the accuracy of any information provided by outside sources.UIAs we disclaim any representation concerning source reliability, readers must contact information suppliers on their own and gauge to the reader's satisfaction the truthfulness of any source information. It should be understood that there is no guarantee past performance will be indicative of future results. Any reference to past performance(s) of companies previously advertised are specially selected to be referenced based on the favorable performance of these companies and the companies referenced may not be representative of all past advertised companies as not all past advertised companies may have performed as well. Readers are cautioned that small and micro-cap stocks are high-risk investments and that they may lose all or a portion of their investment if they make a purchase in our advertised stocks. In order to be in full compliance with the U.S. Securities Act of 1933, Section 17(b), we are receiving one hundred and ten thousand shares of Rubicon Medical Corporation from Hindsight Holdings Limited as compensation for the distribution of this and other advertisements. Since we are receiving compensation and hold stock in the advertised company there is an inherent conflict of interest in our statements and opinions and such statements and opinions cannot be considered independent. We will benefit from any increase in share price of the advertised company. We will sell our shares at any time, without notice, be that before, during or immediately after the release of this advertisement. The liquidation of our stock may have a negative impact on the securities of the company liquidated, including decreased market value and/or dilution of the company's securities.TY Furthermore, our associates and/or employees and/or principals may have stock positions in advertised companies purchased in the open market or in private transactions. These positions may be liquidated, without prior notification, even after we have made positive comments regarding the advertised company. It should be understood that any price targets and/or projections mentioned are solely opinions and should not be taken as suggested holding periods. In fact, we will sell our positions in any companies advertised before they reach such target prices. The receipt of this information constitutes your acceptance of these terms and conditions. Reading this advertisement shall not create under any circumstances an offer to buy or sell stock in any company advertised. Nor shall it create any principal-agent relationship between the reader and us. The stocks of advertised companies may trade in fast moving, highly volatile markets, and any reader should observe the trading behavior of any advertised company prior to investing. Advertised stocks are often thinly traded and large sell orders will have a substantially negative impact on share price. Investors in advertised stocks may experience difficulty in selling shares without seeing a decline in market price and may have difficulty in finding ready buyers of their stock. Information within this advertisement contains "forward looking" statements within the meaning of Section 27(a) of the U.S. Securities Act of 1933 and Section 21(e) of the U.S. Securities Exchange Act of 1934. ALAny statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be forward looking statements. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could or might occur. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at and the National Association of Securities Dealers (NASD) at We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at ERTThe NASD has published information on how to invest carefully at its web site. Readers can review all public filings by companies at the SEC s EDGAR page. All information within this advertisement is qualified in its entirety by the detailed information and financial statements of the advertised company contained in its regulatory filings with the SEC.


    Except at listed above, no contact information is available for the entity sending the abovementioned newsletter.

    Topic StockPumpingSpecialSituationsAlert20020807 . { Edit | Ref-By | Attach | Diffs | r1.1 }
    You must register before editing pages or using other extended features on this TWiki system.
    Revision r1.1 - 08 Aug 2002 - 03:30 by EliMantel web search for EliMantel
    Privacy Policy
    Copyright © 2000-2005 by the contributing authors. All material on this collaboration tool is the property of the contributing authors. Collect email addresses here.
    Ideas, requests, problems regarding TWiki? Send feedback.